GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influsplit Tetra™ vaccine produced by licensed process (LP)Biological: Influsplit Tetra™ vaccine produced by investigational process (IP)
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1886
- Registration Number
- NCT02207413
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
Phase 3
Completed
- Conditions
- Malaria
- Interventions
- Procedure: Blood samplingBiological: Malaria Vaccine 257049 (MALARIA-055 PRI)Biological: Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)Biological: TritanrixHepB/Hib (MALARIA-055 PRI)Biological: Cell-culture rabies vaccine (MALARIA-055 PRI)Biological: Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3084
- Registration Number
- NCT02207816
- Locations
- 🇹🇿
GSK Investigational Site, Tanga, Tanzania
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
Phase 2
Terminated
- Conditions
- Telangiectasia, Hereditary Hemorrhagic
- Interventions
- Drug: PazopanibDrug: Placebo
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT02204371
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Infections, Respiratory Tract
- Interventions
- Drug: GSK2140944Other: Placebo
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT02202187
- Locations
- 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States
Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02201238
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression
Phase 1
Completed
- Conditions
- Infections, Respiratory Syncytial Virus
- Interventions
- Other: CXCL1Drug: Danirixin
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT02201303
- Locations
- 🇺🇸
GSK Investigational Site, Syracuse, New York, United States
A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children.
Phase 1
Completed
- Conditions
- Nutritional Status
- Interventions
- Dietary Supplement: Nutritional supplement with micronutrientDietary Supplement: Nutritional supplement without micronutrient
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 109
- Registration Number
- NCT02201225
- Locations
- 🇮🇳
GSK Investigational Site, Bangalore, India
A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- Gastritis
- Interventions
- Drug: Reference mosapride citrate (GASMOTIN)Drug: GR107719B (Formulation 1)Drug: GR107719B (Formulation 2)
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02201316
- Locations
- 🇮🇳
GSK Investigational Site, Hyderabad, India
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT02202161
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ
Not Applicable
Completed
- Conditions
- Oral Hygiene
- Interventions
- Drug: Sodium fluoride (250 ppm)Drug: Sodium fluoride (1150 ppm)Drug: Sodium fluoride (1426 ppm) + zinc base ADrug: Sodium fluoride (1426 ppm)Drug: Fluoride (0 ppm)Drug: Sodium fluoride (1426 ppm) + zinc base B
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 62
- Registration Number
- NCT02195583
- Locations
- 🇺🇸
GSK Investigational Site, Indianapolis, Indiana, United States
© Copyright 2025. All Rights Reserved by MedPath